Todd Bazemore - 28 Jun 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
28 Jun 2021
Net transactions value
-$16,796
Form type
4
Filing time
29 Jun 2021, 17:25:55 UTC
Next filing
28 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale $16,796 -2,911 $5.77 $134,589 28 Jun 2021 Direct F1, F2
holding KALA Common Stock 42 28 Jun 2021 By son F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.
F2 Includes 118,000 unvested RSUs.
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.